2 December 2015 - On September 21 a venture capitalist named Martin Shkreli​, who had just bought the rights to the drug Daraprim, raised its price from $13.50 per pill to $750. It was an increase of 5500 per cent. Daraprim is a critical niche drug for treating toxoplasmosis, which can wreak havoc on people with weakened immune systems, notably AIDS patients.

For more details, go to: http://www.smh.com.au/comment/big-karma-hits-big-pharma-as-biotech-shares-plunge-after-pricegouging-accusations-20151202-gldg59.html